Fertility and Sterility
Volume 92, Issue 6 , Pages 2078-2081 , December 2009

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients

  • Artemis Karkanaki, M.D.

      Affiliations

    • Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    • Corresponding Author InformationReprint requests: Karkanaki Artemis, M.D., Ioanninon Str.30, 54639, Thessaloniki, Greece (FAX: 0030 2310 992915).
    • ,
  • Athanasia Piouka, M.Sc.

      Affiliations

    • Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    • ,
  • Ilias Katsikis, Ph.D.

      Affiliations

    • Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    • ,
  • Dimitrios Farmakiotis, Ph.D.

      Affiliations

    • Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
    • ,
  • Djuro Macut, Ph.D.

      Affiliations

    • Institute of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia
    • ,
  • Dimitrios Panidis, Ph.D.

      Affiliations

    • Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Received 28 April 2009 ,Revised 14 June 2009 ,Accepted 16 June 2009.

References 

  1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236
  3. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146
  4. Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742–746
  5. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132:989–993
  6. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  7. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil Steril. 2004;81:19–25
  8. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296:E238–E243
  9. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine F editor. Polycystic ovary syndrome. Boston: Blackwell Scientific. 1992;377–84
  10. Diamanti-Kandarakis E, Panidis D. Unraveling the phenotyping map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol. 2007;67:735–742
  11. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–488
  12. Yilmaz M, Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25:246–252
  13. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–1603
  14. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–175
  15. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5:129–134
  16. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737
  17. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  18. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005;83:1708–1716
  19. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril. 2009;91:1332–1335
  20. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006;119:356.e1–356.e6
  21. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchón R, Luque-Ramírez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21:257–265
  22. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337–345
  23. Sepilian V, Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig. 2005;12:129–134
  24. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004;27:528–534
  25. Orio F, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:110–115
  26. Orio F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2619–2623
  27. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003;18:1790–1796
  28. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol. 2004;61:738–746
  29. Gulcelik NE, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:511–515
  30. Ducluzeau PH, Cousin P, Malvoisin E, Bonet H, Vidal H, Laville M, et al. Glucose-to-insulin ratio rather than sex-hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626–3631
  31. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with 4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril. 2005;84:538–540
  32. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrinol Rev. 2005;26:439–451
  33. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003;26:2442–2450
  34. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300
  35. Ekmekci H, Ekmekci O. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thrombosis/Hemostasis. 2006;12:163–168
  36. Aroda V, Ciaraldi T, Chang S, Dahan M, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin ratio. Fertil Steril. 2008;89:1200–1208
  37. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocrinol Rev. 1997;18:774–800
  38. Chang RJ, Nakamura RM, Jud HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356–359
  39. Singer S, Pilpel N, Koren I, Boiko V, Hemi R, Pariente C, et al. Adiponectin levels in adolescent girls with polycystic ovary syndrome. Clin Endocrinol. 2009;[Epub ahead of print]
  40. Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti N, Melchionda N. Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res. 1982;14:284–287
  41. Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol. 1983;147:588–592
  42. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–1723
  43. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297–307
  44. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical models to accurately assess insulin resistance in lean, overweight or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273–1276
  45. Trader BC, Pall M, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in a group of women presenting with oligomenorrhea or hirsutism: NIH 1990 vs. Rotterdam 2003 criteria. In: The 88th Annual Meeting of the Endocrine Society. Boston, MA, June 24–28, 2006.
  46. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10:107–117

 A.K. has nothing to disclose. A.P. has nothing to disclose. I.K. has nothing to disclose. D.F. has nothing to disclose. D.M. has nothing to disclose. D.P. has nothing to disclose.

PII: S0015-0282(09)01355-7

doi: 10.1016/j.fertnstert.2009.06.034

Fertility and Sterility
Volume 92, Issue 6 , Pages 2078-2081 , December 2009

Article Tools

* Image Usage & Resolution